Add like
Add dislike
Add to saved papers

ADAM17 regulates p75 NTR -mediated fibrinolysis and nerve remyelination.

Journal of Neuroscience 2022 Februrary 3
We previously reported that ADAM17 is a key protease regulating myelin formation. We now describe a role for ADAM17 during the Wallerian degeneration process. Unexpectedly, we observed that glial ADAM17, by regulating p75NTR processing, cell autonomously promotes remyelination, while neuronal ADAM17 is dispensable. Accordingly, p75NTR abnormally accumulates specifically when ADAM17 is maximally expressed leading to a down-regulation of tPA expression, excessive fibrin accumulation over time and delayed remyelination. Mutant mice also present impaired macrophage recruitment and defective nerve conduction velocity. Thus, ADAM17 expressed in Schwann cells, controls the whole Wallerian degeneration process and its absence hampers effective nerve repair. Collectively, we describe a previously uncharacterized role for glial ADAM17 during nerve regeneration. Based on the results of our study, we posit that, unlike development, glial ADAM17 promotes remyelination through the regulation of p75NTR -mediated fibrinolysis. SIGNIFICANT STATEMENT: The alpha secretase ADAM17, though relevant for developmental PNS myelination, has never been investigated in Wallerian Degeneration. We now unravel a new mechanism of action for this protease and show that ADAM17 cleaves p75NTR , regulates fibrin clearance and eventually fine-tunes remyelination. The results presented in this study provide important insights into the complex regulation of remyelination following nerve injury, identifying in ADAM17 and p75NTR a new signaling axis implicated in these events. Modulation of this pathway could have important implications in promoting nerve remyelination, an often-inefficient process, with the aim of restoring a functional axo-glial unit.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app